Overview

Effect of Rosiglitazone on ADMA in Critical Illness

Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Rosiglitazone,decreases the ADMA concentration and thereby increases the arginine/ADMA ratio of critically ill patients.
Phase:
Phase 3
Details
Lead Sponsor:
VU University Medical Center
Treatments:
Rosiglitazone